AAD Licensed Content

The presentation discusses recent developments in CAR T-cell therapy for autoimmune diseases, highlighting its shift from cancer treatment to addressing conditions like lupus, inflammatory myositis, and…

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

CAR T-Cell Therapy for Autoimmune Diseases: New Insights and Clinical Updates

Description

The presentation discusses recent developments in CAR T-cell therapy for autoimmune diseases, highlighting its shift from cancer treatment to addressing conditions like lupus, inflammatory myositis, and scleroderma. A notable case series featured 15 patients who showed promising clinical responses after receiving CAR T therapy, particularly in terms of reduced autoantibody levels and improved disease scores. However, the therapy’s side effects, including cytokine release syndrome (CRS), were notable, with a significant number of patients requiring treatment for this adverse effect. The presentation also underlines the importance of post-therapy monitoring due to the use of retroviral technology to engineer the T-cells, prompting concerns about long-term safety. In addition, insights from a trial on nemolizumab, an anti-IL-31 receptor monoclonal antibody for prurigo nodularis, emphasize its effectiveness but reveal limitations, such as its short-duration study design and a narrow patient demographic. While the results indicate a potential for significant itch relief, concerns regarding patient selection and side effects, including pulmonary complications, are acknowledged. Overall, the discussion reflects a cautious optimism about the expanding roles of these treatments in managing autoimmune diseases, while also stressing the need for ongoing long-term safety assessments.

View more

Conclusions

  • CAR T cell therapy holds promise for treating autoimmune diseases, with patients showing clinical improvement after treatment.
  • In a case series of patients with autoimmune diseases, CAR T therapy effectively reduced serum autoantibody levels and improved clinical scores.
  • Long-term follow-up displayed durable responses in clinical improvement, although risks of severe side effects, including infections, remain.
  • The treatment may lead to a 'reset' of B cells, with pathogenic B cells not recovering after therapy, thus enhancing treatment efficacy.
  • Future applications of CAR T therapy could expand into non-malignant autoimmune conditions as research progresses.
  • Nemolizumab has shown potential as an effective monotherapy for prurigo nodularis, demonstrating significant reductions in itch and disease severity compared to placebo.
  • Long-term safety and efficacy of both CAR T therapy and nemolizumab require further investigation, particularly concerning the longevity of responses and overall patient safety.
  • Müller F, et al. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. PMID: 38381673.
  • Kwatra SG, et al. N Engl J Med. 2023 Oct 26;389(17):1579-1589. doi: 10.1056/NEJMoa2301333. PMID: 37888917.
  • Datsi A, et al. Allergy. 2021 Oct;76(10):2982-2997. doi: 10.1111/all.14791. Epub 2021 Mar 16. PMID: 33629401.
  • Hashimoto T, et al. J Allergy Clin Immunol. 2023 Mar;151(3):737-746.e6. doi: 10.1016/j.jaci.2022.11.009. Epub 2022 Nov 19. PMID: 36410530.
  • Simpson EL, et al. J Allergy Clin Immunol. 2023 Nov;152(5):1179-1195. doi: 10.1016/j.jaci.2023.05.026. Epub 2023 Jun 13. PMID: 37315812; PMCID: PMC10716365.